10 years after its identification, the tumour suppressor phosphatase and tensin homologue (PTEN) still holds lots of surprises. Three studies, published in Cell, provide insights into how ...

Patterson-UTI (PTEN) delivered earnings and revenue surprises of 100% and 7.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?